PRM203 Bayesian mixed treatment comparison (MTC): A novel method to demonstrate equivalence and non-inferiority  by Malcolm, W.A. & Uthman, O.A.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A49 
 
 
sparse data structures. Separation often leads to failure in convergence of 
maximum likelihood models or unrealistic parameter estimates with wide 
confidence intervals. Therefore, the study objective is to compare the empirical 
performance of alternative methods for modeling sparse data in the context of 
small sample sizes: Firth-bias corrected logistic regression, exact logistic 
regression, penalized logistic regressions macro implemented in STATA, removal 
of the variable causing separation, and a Bayesian logistic model with a weakly 
informative prior (WIP). METHODS: HIPAA compliant diabetes patient records 
were used for determining factors associated with exposure to Medication 
Therapy Management (MTM) services at high frequency. Potential predictors of 
MTM visit frequency included age, gender, medication regimen complexities and 
presence of diabetes-related complications. This dataset had a small sample size 
(n=121) and exhibited separation problem; all patients in the high visit frequency 
group had diabetes with complexity. We compared the results of the Bayesian 
model with a WIP (coefficients are assigned a N(0,1.38) prior) to results of 
deleting the problematic variable, exact logistic regression and two different 
algorithms for penalized log likelihood functions (Firth’s Bias-Correction in SAS 
and a STATA-Macro based routine). RESULTS: The Bayesian model with WIP 
produced odds ratio estimates of high frequency group membership based on 
diabetes complexity within expected range of treatment effects and plausible 
confidence intervals OR=4.64 (CI:0.98, 24.58). Among other models, only Firth-
Bias model converged but parameter estimates and confidence intervals were 
unrealistically large OR=210.9 (CI:1.83, >999.99). Removal of the problematic 
variable (diabetes complexity) from the model prevented assessment of its effect 
on the probability of high visit frequency membership. CONCLUSIONS: Bayesian 
models with WIP represent a useful tool for modeling health outcomes sparse 
data with small sample size.  
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OBJECTIVES: To explore the impact of inferences from very samples on the 
outcome of management decisions. In many cases management has some prior 
belief about the states of nature. We explore the potential advantage of 
incorporating Bayesian inference to improve the confidence in managerial 
decisions based on small samples.. Traditionally, survey researchers reconcile 
differences between survey results and prior beliefs by citing the uncertainty 
reflected in the sampling error or looking for other explanatory factors (such as 
possible survey measurement error). The Bayesian approach integrates the 
different sources of information (i.e., prior belief and observed survey results) to 
arrive at the most probable estimate. In full realization, a Bayesian approach 
considers not just the probability that “truth” lies outside some range of values 
but seeks to estimate the probability of each of many possible hypotheses, given 
the data was that obtained. METHODS: Using responses to a choice-based 
conjoint exercise that was embedded in an online survey of approximately 700 
individuals, we created a series of samples of different sizes using different 
restrictions to reflect the ways in which both probability and convenience 
samples might be generated. We drew multiples of ten random samples of 25, 
50, 75, 100, 150, 225 and 450 from our “population” of 897 respondents, resulting 
in 70 individual samples. We estimated HB models for each sample (using 
Sawtooth Software’s CBC-HB program). RESULTS: Simulated choice 
probabilities–a key output of discrete choice models–stabilize across samples 
starting with n=75. For smaller samples, decision confidence can be increased 
using Bayesian inference and bootstrapping methods. CONCLUSIONS: 
Meaningful inferences—and hence decisions–can be made with smaller sample 
sizes by utilizing Bayesian inference and methods such as bootstrapping to 
better estimate the degree of uncertainty in the data.  
 
PRM199  
UNDERESTIMATION OF UNCERTAINTIES IN HEALTH UTILITIES DERVIED  
FROM MAPPING ALGORITHMS INVOLVING HEALTH-RELATED QUALITY OF  
LIFE MEASURES: STATISTICAL EXPLANATIONS AND POTENTIAL  
REMEDIES  
Chan K1, Willan A2, Gupta M3, Pullenayegum E3 
1University of Toronto, Toronto, ON, Canada, 2Dalla Lana School of Public Health, Toronto, ON, 
Canada, 3McMaster University, Hamilton, ON, Canada  
OBJECTIVES: Health utilities (HUs) are required to conduct cost-utility analyses 
(CUAs). Often, health-related quality of life (HRQOL) data, instead of HUs, are 
collected in clinical trials. Increasingly, mapping algorithms have been 
developed to derive HUs from HRQOL data. However, the variance of the derived 
HUs based on mapping are observed to be smaller than those of the actual HUs. 
METHODS: Two reasons are proposed: (1) the presence of important 
unmeasured predictors leading to a high degree of unexplained variance of 
derived HUs, and (2) ignoring that the regression coefficients are random 
variables themselves. We derive three variance estimators of HUs to account for 
these reasons: (1) R2-adjusted estimator, (2) parametric estimator and (3) non-
parametric estimator. We tested these estimators using a simulated dataset and 
a real dataset involving EQ-5D and University of Washington Quality of Life 
questionnaire for patients with head and neck cancers. RESULTS: The R2 
adjusted estimator can be used in ordinary least square (OLS) based mapping 
algorithms and requires only the R2from the derivation study. The parametric 
estimator can be used in OLS based mapping algorithms and requires the mean 
square error (MSE) and the design matrix from the derivation study. The non-
parametric estimator can be used in any mapping algorithm and requires leave-
one-out cross-validation MSE from the derivation study. In the simulated 
dataset, all three estimators are within 1% of the variance of the actual HUs. In 
the real dataset, the unadjusted variance was 44% less than the actual variance, 
while all three estimators are within 10% of the actual variance. CONCLUSIONS: 
When conducting CUA based on mapping algorithms, the variance of derived 
HUs should be properly adjusted using one of the proposed methods so that the 
results of the CUA will have the appropriate degree of uncertainty.  
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OBJECTIVES: In survey questions where the variable of interest is quantitative, 
responses often involve selecting one of several mutually exclusive intervals in 
which the variable lies within (denoted interval data). This precludes one from 
using many of the popularly reported measures of center (mean, median, mode, 
etc.). To this end, a simple estimator is proposed to estimate the population 
mean, μ, when the data are intervaled and its properties are studied. METHODS: 
For estimation of μ given intervaled data, we propose the Weighted Interval 
Midpoint Estimator (WIME). Expressions for its expected value and variance are 
derived. These are then calculated for normal distributions and a χ2 distribution 
on 1 degree of freedom using various interval configurations. Bootstrapping 
methods are then proposed to obtain estimates of the sampling distribution of 
the WIME as well as the sample mean given the interval counts. RESULTS:  
In general, the WIME is a biased estimator of μ; this bias is the same for all 
sample sizes. Simple bounds for the bias can derived. Both the bias and variance 
of the estimator depend on the choice of intervals. In the case of the normal 
distribution, equal-length intervals produce estimates with seemingly no  
bias and variance slightly above that of the sample mean as opposed to a  
non-equal-length configuration, even if the intervals are not symmetric about  
μ. For the χ2 distribution on 1 degree of freedom, using equal-length intervals 
produces estimates with less bias and variance than when using non- 
equal-length intervals. CONCLUSIONS: While the WIME is a quick and  
easy method to estimate μ, its performance depends on the intervals chosen. 
Thus prudence must be taken when selecting them. In the event no prior 
information exists to guide the process, equal-length intervals seem to be a safe 
fallback.  
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OBJECTIVES: 1) To examine the practice of calculating a sample mean cost for 
each of two or more cohorts, reporting the difference(s) as the incremental 
cost(s), and reconciling this practice against the common assumption that the 
underlying expenditures follow a two-parameter gamma distribution, and 2) To 
revisit the interpretation of incremental costs based on the difference in sample 
means as the properties of the assumed underlying gamma distribution vary. 
METHODS: Monte Carlo gamma distribution simulation in SAS version 9.3 
varying the shape and scale parameters for the simulations and displaying the 
results in graphical and tabular format. RESULTS: It is possible to create 
examples of simulated data sets where the sample means have values that can 
be in excess of the estimated 75th percentile. CONCLUSIONS: An analyst should 
be cautious in his or her reporting of incremental costs as the lay consumer of 
these quantities may interpret the difference in the means like they would for 
two or more somewhat symmetrical distributions where the mean can represent 
the center. However, this interpretation might be misleading depending on the 
magnitude of the shape and scale parameters that characterize an underlying 
distribution's behavior.  
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OBJECTIVES: When evaluating multiple drugs for equivalence (or non-
inferiority) within the context of a Bayesian MTC, most studies base their 
interpretation solely on the point estimates and respective credible intervals. 
The following novel methodology advances interpretation by: Incorporating a 
pre-specified minimal clinically important difference (MCID); presenting a direct 
probability of equivalence (or non-inferiority), and graphically depicting how the 
probability varies by MCID. METHODS: As an illustrative example, we applied 
MTC to compare 12-week HbA1c reduction with vildagliptin 50 mg bid vs. 
sitagliptin 100 mg qd as monotherapies in patients with type 2 diabetes. 
Equivalence was assessed with a predefined equivalence margin of MCID. A 
Bayesian approach has the advantage of being able to provide probability 
statements for equivalence, to make direct inferential statement that the 
treatment effect between the two comparisons is between the specified lower 
and upper MCID (HbA1c ±0.7). The posterior probability of equivalence is 
calculated based on the area under the curve between lower and upper MCID on 
distribution of the mean change in HbA1c between the two comparisons. 
Sensitivity analysis was conducted by varying MCID values. RESULTS: The 
results of the MTC showed no significance difference between the two 
interventions in the reduction of HbA1c at 12 weeks (Δ = 0.16; 95% CrI -0.20 to 
0.52). However, this evidence of “no significant difference” does not prove 
equivalence. Applying the new method, at 12 weeks follow-up, the probability 
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that vildagliptin 50 mg bid and sitagliptin 100 mg qd are equivalent is 99.3%. The 
result of a sensitivity analysis showed that the probability of the two drugs 
remaining equivalent remains high (>90%) over a wide range of MCIDs. 
CONCLUSIONS: This innovative method has the potential to improve 
understanding of equivalence (or non-inferiority) between drugs for multiple 
stake-holders.  
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OBJECTIVES: Applying propensity scores from confounders and their 
interactions, we observed the effect of reducing the number of digits for 
propensity score matching including resulting outcome point estimates. 
METHODS: We included sex, race, education, marital status, census region, year, 
age, insurance, and all pair-wise interactions for a 7 digit propensity score 
quantifying the conditional probability of low income status. Using 10 years of 
Medical Expenditure Panel Survey data, we assessed the association of low 
income status and experiencing an emergency room visit. We incrementally 
reduced matched propensity score digits from 7 to 2, observing effects on sample 
size, standardized differences in confounders, differences in covariate variance, 
odds ratio [OR] estimates, and Akaike Information Criterion [AIC]. RESULTS: 
Generally, fewer matching digits exacerbated differences in confounders 
between the matched sets. However, six digit matching was superior to  
seven-digit matching in confounder differences (standardized differences  
[SD] of 0 versus .01 respectively) as was 3 digit versus 4  
digit matching (SD of 3.39 versus 3.99 respectively). The pattern of variance 
differences was identical to the SD differences. Sample size was largest with 2 
digit matching (n=80,624), progressively diminishing with each additional  
digit matched (7 digit matching had n=61,168). AIC inflated inversely with digit 
reduction: 47,298.99 for 7 digit matching and 63,660.528 for 2 digit matching.  
ORs were consistent throughout (smallest OR=1.355 with 4 digits and largest 
OR=1.386 with 6 digits). CONCLUSIONS: Propensity score matching seeks  
to minimize differences between exposure groups. When propensity scores  
are generated using interaction terms, matching on a greater number of  
digits may not produce a better matched set of exposed and unexposed  
groups in terms of confounders. Analysts must consider the mechanism  
in which propensity scores are produced when specifying the matching 
algorithm.  
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OBJECTIVES: To evaluate an online, freeware JavaScript program that can be 
utilized in the generation and graphical illustration of alternative distributions 
and generate raw data for exploring cost effectiveness models. For this 
evaluation, beta, gamma and normal distributions were compared for a web-
based resource. METHODS: For evaluation, we compared the results between 
jStat.org and R statistical software. jStat is intended as a code library written in 
JavaScript that allows one to perform advanced statistical operations without the 
need of more resource intensive software (such as MS Excel or R). The jStat 
graphic and plotting functionality is based on the jQuery Flot plugin. RESULTS: 
Analysis of a mix of distributions from jStat (n = 100) versus R (n=100) found the 
following summary of results for the two-sample Kolmogorov-Smirnov test. Beta 
distributions (alpha = 8, beta = 2): (medians: 0.807 vs. 0.819) D = 0.16, p-value = 
0.549; gamma distributions (shape = 5, scale = 5): (medians: 23.5 vs. 26.9) D = 0.11, 
p-value = 0.581; and normal distributions (mean = 100, stdev = 10): (medians: 
101.6 vs. 101.3) D = 0.13, p-value = 0.366. CONCLUSIONS: jStat is designed to 
perform in most major browsers and operating systems. jStat applies 
complicated statistical functions that may be slower with handheld processors. 
There are a growing number of calculators on the internet that utilize JavaScript 
and java for the generation and plotting of such datasets. R and MS Excel remain 
popular and powerful resources that are frequently used in economic analyses 
and modeling that includes the generation of datasets with various statistical 
distributions. jStat may be useful for generating and examining pilot data or 
exploring the health economic ramifications of a clinical publication when the 
full patient dataset is not readily available.  
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OBJECTIVES: Studies that estimate incidence of very rare diseases (less than 1 in 
100,000 of the general population) often use cases seen at specialized centers. 
However, multiple potential sources of both systematic error and random error 
complicate this estimation. We calculated the incidence rate of Multicentric 
Castleman’s Disease (MCD) based on data from two specialized centers. Our 
objective is to describe the main challenges of incidence estimation of rare 
diseases in general, and specifically of MCD, and to suggest how to improve the 
assessment accuracy. METHODS: All the patients that were newly diagnosed 
with MCD at 2 centers were included. Patients’ locations were identified from the 
first 3 digit of their zip codes and mapped using a Geographical Information 
system (GIS). Catchment areas for each center were defined based on spatial 
patterns and center-specific clinician input. CENSUS data were used to estimate 
the size of the reference population and to calculate the crude and stratified 
incidence rates. RESULTS: Uncertainty resulted from small sample size; center-
specific population features and referral patterns; under-diagnosis and difficulty 
of diagnosis; association between disease risk factors and proximity to the 
centers; and difficulty with defining a catchment area to establish the relevant 
population denominator. Analysis involved a trade-off between the number of 
patients included in a catchment area and catchment area definition, with 
clearer geographical boundaries that maximized the proportion of MCD patients 
in the population represented in the center. CONCLUSIONS: Small sample sizes 
in combination with multiple potential sources of error challenge an accurate 
estimate of incidence. Finer definitions of each center catchment area further 
reduce the number of included cases but can improve the accuracy of the 
incidence estimate.  
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OBJECTIVES: the research aims to design and develop cost senstivity simulators 
both with intention and effective data on impact of economics on decision 
points in clinical practices. At this point mainly drug treatment and some 
diagnostic decisions with lab tests have been investigated. This step deals with a 
milestone to move from static to dynamic econometric modeling for reliable 
physicians’s cost awareness estimates on how patients ‘economic influence 
decisions, at the point of visits, for labtests and treatment decisions; by 
investigating various sources of changes in the survey. METHODS: several 
calibration issues are investigated following the first series of runs with the 
Physician National Ambulatory Medicare Survey. The analytical data sets used 
have been designed on diabetes, hypertension and asthma. Populations are 
identified with ICD codes, drug lists are also used to ascertain the population 
under study. Drug treatments are identified with drug codes, originally from the 
NDC and generic codes; the successive analytical datasets extracted from the 
NAMCS physician survey are used to estimate reliable estimates on impact of 
insurance and payment/billing systems, controlling for changes due to drug 
codes, ICD classification, categorization of patients, stages of computerization of 
EHRs, including reports on lab and diagnostic tests. RESULTS: The test of the 
dynamic modeling to adjust over time the disease models will lead to a synopsis 
of the different results from studies initiated since 2003. Comparison of results 
across three diseases already demontrate the consistency of the effects of the 
selected variables on insurance and payment or billing. It allows to identify 
conditions of replicability of the survey designs and to quantify the scope of 
biases. CONCLUSIONS: This stage of development will lead to propose reliable 
adjustement methods to integrate the various changes affecting the physician 
survey and the constitution of reliable analytical datasets extracted from that 
survey on major chronic conditions.  
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OBJECTIVES: Immortal time bias (ITB), the inclusion of person-time during 
which the study outcome cannot occur, has been shown to bias study findings. 
We examine the impact of ITB by estimating the effect of chemotherapy  
on overall survival, and demonstrate how landmark analysis can correct  
the bias. METHODS: Retrospective study using the MarketScan® Research 
Databases with commercially and Medicare insured individuals linked to the 
Social Security Administration Death records. Subjects with newly diagnosed 
metastatic breast cancer (ICD-9-CM 174.x plus additional codes 196.xx-199.xx) 
and ≥1 year of continuous enrollment prior to breast cancer diagnosis were 
identified. Chemotherapy exposure was defined as ≥3 chemotherapy claims 
following metastatic cancer diagnosis. Landmark analysis was used to estimate 
survival rates conditional on surviving to certain time points to adjust for  
ITB. Time to death or censoring was determined for the full sample and patients 
who survived 1, 3, 6 and 12 months. RESULTS: A total of 5759 metastatic breast 
cancer patients were identified of which 2932 had ≥3 claims for chemotherapy 
during follow-up. Average survival time for chemotherapy patients was 9.0 
months longer than patients with <3 chemotherapy claims. The difference in 
survival times between patients with and without chemotherapy decreased as 
patients were required to survive for longer periods of time: 1-month survival = 
+8.9 months, 3-month survival = +7.0 months, 6-month survival = +6.7 months, 
12-month survival = +7.0 months. The artificially increased effect of 
chemotherapy in the full sample analysis was due to the time between 
metastatic cancer diagnosis and third chemotherapy claim being “immortal” for 
the chemotherapy patients (median 2.6 months). CONCLUSIONS: Landmark 
analysis can be used to account for immortal time bias in oncologystudies 
analyzing the effect of new treatments or the comparative effectiveness of 
current treatments. However, an appropriate landmark must be chosen as 
results can be affected.  
